Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24209194 | 0.87 | DHODH (0.66) | MEN1KMT2ADHODHL3MBTL1ALDH1A1 | |
| SCHEMBL18613113 | 0.87 | DHODH (0.66) | MEN1KMT2ADHODHL3MBTL1ALDH1A1 | |
| SCHEMBL2463602 | 0.86 | TAOK1 (0.55) | ALDH1A1 | |
| SCHEMBL24804264 | 0.85 | EPHX2 (0.60) | EPHX2MEN1KMT2ADHODHL3MBTL1 | |
| SCHEMBL9025395 | 0.84 | PYGL (0.46) | EPHX2ACE | |
| SCHEMBL3375614 | 0.82 | PDE4A (0.52) | EPHX2MEN1KMT2AALDH1A1 | |
| SCHEMBL30468602 | 0.82 | PDE4A (0.52) | EPHX2MEN1KMT2AALDH1A1 | |
| SCHEMBL3375618 | 0.82 | PDE4A (0.52) | EPHX2MEN1KMT2AALDH1A1 | |
| SCHEMBL30047267 | 0.82 | PDE4A (0.52) | EPHX2MEN1KMT2AALDH1A1 | |
| SCHEMBL5970025 | 0.81 | ALDH1A1 (0.61) | EPHX2MEN1KMT2ADHODHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0738149-B1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 2006-11-29 | — | — | EP | disclosed |
| US-6528685-B2 | Such as (R)-N-(2-acetamido)-1-aminoindan for treatment of Parkinson's disease, dementia, epilepsy, convulsions, or seizures | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-03-04 | — | — | US | disclosed |
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | COHEN SASSON (IL) | 2002-06-06 | — | — | US | disclosed |
| US-6271263-B1 | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2001-08-07 | — | — | US | disclosed |
| US-5994408-A | THERAPY FOR PARKINSON'S DISEASE; ANTICONVULSANT | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-11-30 | — | — | US | disclosed |
| EP-0738149-A4 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1999-10-27 | — | — | EP | disclosed |
| US-5914349-A | ANTICONVULSANTS, EPILEPSY AND COGNITIVE AGENTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-06-22 | — | — | US | disclosed |
| US-5880159-A | TREATING ACUTE NEUROLOGICAL TRAUMATIC DISORDER OR NEUROTRAUMA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-09 | — | — | US | disclosed |
| US-5877221-A | TREATING DEMENTIA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | disclosed |
| US-5877218-A | PARKINSON'S DISEASE; ANTIEPILEPSY AGENTS; ANTICONVULSANTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | disclosed |
| US-5639913-A | TREATMENT OF PARKINSON'S DISEASE, DEMENTIA, EPILEPSY | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-06-17 | — | — | US | disclosed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996021640-A1 | OPTICALLY ACTIVE AMINOINDANE DERIVATIVES AND PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-07-18 | — | — | WO | disclosed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | PARK7, GAP43, PSEN1 | EPHX2 1275/4885MEN1 142/4885KMT2A 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.